ERYTECH positions its lead product in solid tumors and launches a Phase II clinical study in pancreatic cancer

  • Post author:
  • Post category:Newsroom

ERYTECH provides an update on its development plans to broaden the scope of its lead product eryaspase into the large field of solid tumors and announces the launch of a Phase II study in pancreatic cancer.

Menu